
A New Genetic Test Can Identify People at 10 Times Higher Glaucoma Risk — And May Predict Who Needs Surgery
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/a-new-genetic-test-can-identify-people-at-10-times-higher-glaucoma-risk-and-may-predict-who-needs-surgery
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
A New Genetic Test Can Identify People at 10 Times Higher Glaucoma Risk — And May Predict Who Needs Surgery Short answer: The November 2026 study reports a major improvement in genetic risk prediction for open-angle glaucoma. In one Australian group of European ancestry, people in the highest 10% of the score had about 10 times the odds of glaucoma compared with the other 90%. The score also tracked with earlier population-level onset, treatment escalation, and glaucoma surgery in selected cohorts. But those results do not mean that everyone in the top 10% has a 10-fold chance of getting glaucoma, that the test can tell an individual when they will develop it, or that a high score by itself justifies laser or surgery. The strongest evidence is for ranking risk of developing glaucoma. Evidence that the new score independently predicts progression after diagnosis—and that acting on the score prevents blindness—is much less complete. The study, “Step change in glaucoma polygenic risk score performance enables clinical utility,” was published online in Ophthalmology on November 11, 2026. This assessment reflects evidence available as of November 18, 2026. () What the study did—and what “more than 6 million people” means The researchers combined genome-wide association study data on 297,871 people with glaucoma and 6,524,164 controls. They also brought in genetic studies of intraocular pressure, vertical cup-to-disc ratio—a measure of optic nerve shape—and ocular hypertension. The ocular-hypertension data included 54,968 cases and 486,639 controls; the other two traits included 159,452 and 111,724 people, respectively. These groups can overlap: one person may contribute data to more than one trait study. So “more than 6 million” describes the scale of the contributing data, not necessarily 6 million unique people. () The discovery data and ancestry A major input was a 23andMe glaucoma study involving approximately 4.5 million people, including 135,000 people reporting glaucoma. It included people of European, African American, and Hispanic or admixed American ancestry. The researchers combined those results with other glaucoma and eye-trait studies, including data from the United Kingdom Biobank, the Canadian Longitudinal Study on Aging, the International Glaucoma Genetics Consortium, the Global Biobank Meta-analysis Initiative, FinnGen, and the Million Veteran Program. The study’s public main text does not give a complete ancestry-by-ancestry breakdown of all discovery cases and controls. () The largest discovery inputs were not equally balanced across ancestry groups. The main score was built from European, African, and admixed American/Hispanic results. A separate East Asian score was explored but did not improve prediction in the study’s East Asian test group; the South Asian data were too limited to build a similarly powered ancestry-specific score. The researchers instead used a combined score and standardized its ranking within ancestry groups. () There is also phenotype uncertainty in some discovery data. Many 23andMe cases reported their own glaucoma diagnosis, whereas other datasets used medical records or clinical examination. Self-report can include incorrect diagnoses or different glaucoma types. The authors used broad, very large datasets to increase statistical power, but sample size does not make every diagnosis equally precise. () How the new score was built A polygenic risk score combines the small effects of many genetic variants into one number. The new score used about 7 million single-nucleotide variants with nonzero weights. Rather than selecting only a small set of variants that passed strict significance thresholds, the researchers used SBayesRC, a method designed to estimate the combined effects of variants across the genome. They first built scores for different ancestry groups, then combined them into one score. The combination weights were estimated using 75% of a European-ancestry National Eye Institute glaucoma case-control dataset; the remaining 25% was held out for testing. () The “multi-trait” part is important: the researchers used genetic evidence related to glaucoma, eye pressure, optic nerve shape, and ocular hypertension to improve estimates of genetic risk. They did not use the patient’s current eye-pressure measurement or optic nerve photograph to calculate the saliva-test result. For the European-ancestry data, they also adjusted the glaucoma genetic results to account for genetic effects related to corneal thickness. That is not the same as measuring a patient’s corneal thickness or including it in the test report. () The headline results: what was actually compared The following comparisons are the odds of being a glaucoma case, not the percentage of people who will develop glaucoma. The score’s reported percentile is a person’s position relative to others in a comparison group; it is not itself a probability of disease. For the full table, please open this article on visualfieldtest.com. The study also combined small Australian East Asian and South Asian groups with ancestry-matched controls. Those groups were too small to support dependable estimates at every score cutoff. All reported performance results are from the study’s validation analyses; case and control selection differed between cohorts, so the numbers should not be treated as interchangeable. () The 10.04 comparison is not a universal “10-fold risk” The 10.04 odds ratio is from European-ancestry participants in the Australian and New Zealand Registry of Advanced Glaucoma. It compares the top 10% of that group’s score distribution with the remaining 90%. It does not compare the top 10% with the lowest 10%, and it is not a universal result for every ancestry or population. The study’s own United Kingdom Biobank European-ancestry estimate was 4.91, not 10.04. In African-ancestry groups, the top-10%-versus-rest odds ratio ranged from 2.26 to 3.81, depending on the cohort. Differences in how cases and controls were identified, as well as the higher baseline frequency of glaucoma in some populations, affect these comparisons. () An odds ratio is not an absolute risk. As a simplified illustration, if the other 90% had a 1% probability of glaucoma, an odds ratio of 10.04 would correspond to a probability of about 9.2% in the top decile—not exactly 10%. If the comparison group’s starting probability were different, the top group’s probability would be different too. That illustration is not a risk estimate for any particular person. How much better was it than the older score? In the same Australian and New Zealand registry comparison, the older score had an odds ratio of about 4.2 for the top 10% versus the remaining 90%. The new score’s odds ratio was 10.04. The area under the curve rose from 0.696 to 0.794 in that cohort. The area under the curve describes how often a score ranks a randomly selected case above a randomly selected control; it is not a percentage of people correctly diagnosed. () The improvement also appeared in the African American cohort: the top-decile-versus-rest odds ratio rose from 1.86 with the older score to 3.81 with the new one. Still, the new score is not uniformly as strong outside European ancestry groups. () The older score, published in 2020, used a smaller discovery dataset and a much smaller set of selected variants. That study had already linked genetic score to earlier diagnosis, retinal nerve fiber layer loss, and surgery. The new study’s advance is not the first suggestion that genetics matters; it is the much larger data scale, improved prediction, and broader validation. () Does it predict glaucoma decades earlier? The study supports earlier population-level risk—not an individual diagnosis date 25 years in advance. For the age comparison, the researchers used the Blue Mountains Eye Study, an Australian population-based cohort with eye examinations. They fitted a model using age, sex, and genetic-score percentile, then estimated the age at which modeled glaucoma prevalence reached 3% in each score group. The 3% threshold was chosen as a reference level for population prevalence. The highest and lowest score deciles differed by about 25 years in when they reached that modeled prevalence. () That is not a claim that every person in the highest decile will be diagnosed exactly 25 years before a person in the lowest decile. It is a comparison of modeled prevalence across groups in one population-based cohort. The study also reported absolute-risk estimates. For example, its model estimated that a healthy 65-year-old of European ancestry in the top 20% of the score distribution had about a 10% risk over the next 10 years, compared with 0.4% in the bottom 20% and 1.0% at the median score. These are model-based estimates, not universal numbers for every 65-year-old. In the fully examined Blue Mountains cohort, the observed prevalence was about 20% in the top decile and 0.7% in the bottom decile among participants aged 60 to 97. That older cohort’s prevalence is not the same thing as a young adult’s lifetime risk. () The fully examined cohort is particularly useful for risk estimation, but it had only 81 glauc
Flere episoder fra "Glaucoma, Vision & Longevity: Supplements & Science"



Gå ikke glip af nogen episoder af “Glaucoma, Vision & Longevity: Supplements & Science” - abonnér på podcasten med gratisapp GetPodcast.








